Cite

Abstract A118: CD103+/PD-1+ T-cells identify a subset of triple-negative breast cancer eligible for targeted checkpoint inhibition

MLA

Giulia Bottai, et al. “Abstract A118: CD103+/PD-1+ T-Cells Identify a Subset of Triple-Negative Breast Cancer Eligible for Targeted Checkpoint Inhibition.” Cancer Immunology Research, vol. 4, Oct. 2016, p. A118. EBSCOhost, https://doi.org/10.1158/2326-6066.imm2016-a118.



APA

Giulia Bottai, Libero Santarpia, & Massimo Roncalli. (2016). Abstract A118: CD103+/PD-1+ T-cells identify a subset of triple-negative breast cancer eligible for targeted checkpoint inhibition. Cancer Immunology Research, 4, A118. https://doi.org/10.1158/2326-6066.imm2016-a118



Chicago

Giulia Bottai, Libero Santarpia, and Massimo Roncalli. 2016. “Abstract A118: CD103+/PD-1+ T-Cells Identify a Subset of Triple-Negative Breast Cancer Eligible for Targeted Checkpoint Inhibition.” Cancer Immunology Research 4 (October): A118. doi:10.1158/2326-6066.imm2016-a118.